{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:51:00Z","timestamp":1776693060598,"version":"3.51.2"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40261-022-01170-6","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T14:34:04Z","timestamp":1655130844000},"page":"611-622","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Temporal Trends in Grade 3\/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma"],"prefix":"10.1007","volume":"42","author":[{"given":"Daniel M.","family":"Geynisman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricio","family":"Burotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria T.","family":"Bourlon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Huo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Del Tejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ella X.","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoran","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith A.","family":"Betts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8298-0289","authenticated-orcid":false,"given":"Bradley","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"issue":"3","key":"1170_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14740\/wjon1279","volume":"11","author":"SA Padala","year":"2020","unstructured":"Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11(3):79\u201387. https:\/\/doi.org\/10.14740\/wjon1279.","journal-title":"World J Oncol."},{"key":"1170_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.566070","author":"M Levitin","year":"2020","unstructured":"Levitin M, Ofori J, Shin WJ, Huang J, Daly M, Cao D, et al. Radiation and checkpoint inhibitor immunotherapy lead to long term disease control in a metastatic RCC patient with brain metastases. Front Oncol. 2020. https:\/\/doi.org\/10.3389\/fonc.2020.566070.","journal-title":"Front Oncol"},{"key":"1170_CR3","unstructured":"National Cancer Institute, Surveillance, Epidemiology, and End Results Program (SEER): Cancer Stat Facts: Kidney and Renal Pelvis Cancer. 2020. https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html. Accessed 13 Jan 2021."},{"issue":"14","key":"1170_CR4","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277\u201390. https:\/\/doi.org\/10.1056\/NEJMoa1712126.","journal-title":"N Engl J Med"},{"issue":"2","key":"1170_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115\u201324. https:\/\/doi.org\/10.1056\/NEJMoa065044.","journal-title":"N Engl J Med"},{"issue":"3","key":"1170_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamaoncol.2018.4604","volume":"5","author":"S George","year":"2019","unstructured":"George S, Rini BI, Hammers HJ. Emerging role of combination immunotherapy in the first-line treatment of advanced renal cell carcinoma: a review. JAMA Oncol. 2019;5(3):411\u201321. https:\/\/doi.org\/10.1001\/jamaoncol.2018.4604.","journal-title":"JAMA Oncol"},{"issue":"8","key":"1170_CR7","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1303989.","journal-title":"N Engl J Med"},{"issue":"4","key":"1170_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.clgc.2018.04.005","volume":"16","author":"BI Rini","year":"2018","unstructured":"Rini BI, Hutson TE, Figlin RA, Lechuga MJ, Valota O, Serfass L, et al. Sunitinib in patients with metastatic renal cell carcinoma: clinical outcome according to international metastatic renal cell carcinoma database consortium risk group. Clin Genitourin Cancer. 2018;16(4):298\u2013304. https:\/\/doi.org\/10.1016\/j.clgc.2018.04.005.","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"1170_CR9","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12885-018-4117-z","volume":"18","author":"R Maroun","year":"2018","unstructured":"Maroun R, Mitrofan L, Benjamin L, Nachbaur G, Maunoury F, Le Jeunne P, et al. Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: retrospective analysis of cross-sectional data. BMC Cancer. 2018;18(1):214. https:\/\/doi.org\/10.1186\/s12885-018-4117-z.","journal-title":"BMC Cancer"},{"key":"1170_CR10","unstructured":"US Food & Drug Administration: FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma. 2018. https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm604685.htm. Accessed 5 Apr 2020."},{"key":"1170_CR11","unstructured":"US Food & Drug Administration: FDA approves avelumab plus axitinib for renal cell carcinoma. 2019. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-avelumab-plus-axitinib-renal-cell-carcinoma. Accessed 14 Mar 2021."},{"key":"1170_CR12","doi-asserted-by":"crossref","unstructured":"US Food & Drug Administration: FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma. 2019. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-plus-axitinib-advanced-renal-cell-carcinoma. Accessed 26 May 2021.","DOI":"10.1097\/01.COT.0000554508.51504.9e"},{"key":"1170_CR13","unstructured":"US Food & Drug Administration: FDA approves nivolumab plus cabozantinib for advanced renal cell carcinoma. 2021. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-nivolumab-plus-cabozantinib-advanced-renal-cell-carcinoma. Accessed 14 Mar 2021."},{"key":"1170_CR14","unstructured":"US Food & Drug Administration: FDA approves lenvatinib plus pembrolizumab for advanced renal cell carcinoma. 2021. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lenvatinib-plus-pembrolizumab-advanced-renal-cell-carcinoma. Accessed 14 Aug 2021."},{"issue":"9","key":"1170_CR15","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2026982.","journal-title":"N Engl J Med"},{"key":"1170_CR16","unstructured":"Choueiri TK: ESMO Virtual Congress: nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase 3 CheckMate 9ER trial. 2020. https:\/\/www.urotoday.com\/conference-highlights\/esmo-2020\/kidney-cancer\/124546-esmo-virtual-congress-2020-invited-discussant-first-results-from-the-randomized-phase-3-checkmate-9er-trial.html. Accessed 26 Jan 2021."},{"key":"1170_CR17","unstructured":"Huo S, Del Tejo V, Du EX, Wu A, Chen Y, Betts KA. Number needed to treat and cost per progression-free survivor of nivolumab plus cabozantinib vs. pembrolizumab plus axitinib for previously untreated advanced renal cell carcinoma. Academy of Managed Care Pharmacy (AMCP). Chicago, IL; 2022."},{"issue":"9","key":"1170_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563\u201380. https:\/\/doi.org\/10.1038\/s41571-019-0218-0.","journal-title":"Nat Rev Clin Oncol"},{"key":"1170_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.736860","author":"S Li","year":"2021","unstructured":"Li S, Li J, Peng L, Li Y, Wan X. Cost-effectiveness of nivolumab plus cabozantinib versus sunitinib as a first-line treatment for advanced renal cell carcinoma in the United States. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.736860.","journal-title":"Front Pharmacol"},{"key":"1170_CR20","unstructured":"Agency for Healthcare Research and Quality: HCUP Cost-to-Charge Ratio Files (CCR). (2006\u20132009). www.hcup-us.ahrq.gov\/db\/state\/costtocharge.jsp. Accessed 5 Apr 2020."},{"key":"1170_CR21","unstructured":"Agency for Healthcare Research and Quality: HCUP National Inpatient Sample (NIS). 2012. www.hcup-us.ahrq.gov\/nisoverview.jsp. Accessed 5 Apr 2020."},{"key":"1170_CR22","unstructured":"Agency for Healthcare Research and Quality: HCUPnet, Healthcare Cost and Utilization Project. 2020. https:\/\/hcupnet.ahrq.gov\/. Accessed 5 Apr 2020."},{"key":"1170_CR23","unstructured":"US Medical Care Services: Consumer Price Index\u2014All Urban Consumers. http:\/\/data.bls.gov\/cgi-bin\/surveymost?cu Accessed 5 Apr 2020."},{"key":"1170_CR24","unstructured":"National Cancer I. Common terminology criteria for adverse events (CTCAE). [Bethesda, Md.]: U.S. Dept. of Health and Human Services, National Institutes of Health, National Cancer Institute; 2010."},{"issue":"17","key":"1170_CR25","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714\u201368. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1170_CR26","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.2217\/fon-2021-1109","volume":"18","author":"DM Geynisman","year":"2022","unstructured":"Geynisman DM, Du EX, Yang X, Sendhil SR, Tejo VD, Betts KA, et al. Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma. Future Oncol. 2022;18(10):1219\u201334. https:\/\/doi.org\/10.2217\/fon-2021-1109.","journal-title":"Future Oncol"},{"issue":"13","key":"1170_CR27","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1016\/j.ejca.2010.06.121","volume":"46","author":"TE Hutson","year":"2010","unstructured":"Hutson TE, Bellmunt J, Porta C, Szczylik C, Staehler M, Nadel A, et al. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer. 2010;46(13):2432\u201340. https:\/\/doi.org\/10.1016\/j.ejca.2010.06.121.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1170_CR28","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.eururo.2015.07.006","volume":"69","author":"C Porta","year":"2016","unstructured":"Porta C, Gore ME, Rini BI, Escudier B, Hariharan S, Charles LP, et al. Long-term safety of sunitinib in metastatic renal cell carcinoma. Eur Urol. 2016;69(2):345\u201351. https:\/\/doi.org\/10.1016\/j.eururo.2015.07.006.","journal-title":"Eur Urol"},{"key":"1170_CR29","doi-asserted-by":"publisher","first-page":"175883592095019","DOI":"10.1177\/1758835920950199","volume":"12","author":"Y Su","year":"2020","unstructured":"Su Y, Fu J, Du J, Wu B. First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis. Ther Adv Med Oncol. 2020;12:1758835920950199. https:\/\/doi.org\/10.1177\/1758835920950199.","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"1170_CR30","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1253\/circrep.CR-21-0008","volume":"3","author":"H Kadowaki","year":"2021","unstructured":"Kadowaki H, Ishida J, Akazawa H, Yagi H, Saga-Kamo A, Umei M, et al. Axitinib induces and aggravates hypertension regardless of prior treatment with tyrosine kinase inhibitors. Circ Rep. 2021;3(4):234\u201340. https:\/\/doi.org\/10.1253\/circrep.CR-21-0008.","journal-title":"Circ Rep"},{"issue":"3","key":"1170_CR31","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1634\/theoncologist.2017-0335","volume":"23","author":"M Schmidinger","year":"2018","unstructured":"Schmidinger M, Danesi R. Management of adverse events associated with cabozantinib therapy in renal cell carcinoma. Oncologist. 2018;23(3):306\u201315. https:\/\/doi.org\/10.1634\/theoncologist.2017-0335.","journal-title":"Oncologist"},{"issue":"1","key":"1170_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/j.seminoncol.2018.11.004","volume":"46","author":"ME Cabanillas","year":"2019","unstructured":"Cabanillas ME, Takahashi S. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Semin Oncol. 2019;46(1):57\u201364. https:\/\/doi.org\/10.1053\/j.seminoncol.2018.11.004.","journal-title":"Semin Oncol"},{"key":"1170_CR33","unstructured":"Postow M. Toxicities associated with checkpoint inhibitor immunotherapy. 2021. https:\/\/www.uptodate.com\/contents\/toxicities-associated-with-checkpoint-inhibitor-immunotherapy. Accessed 2021."},{"issue":"6","key":"1170_CR34","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/liv.13746","volume":"38","author":"DL Suzman","year":"2018","unstructured":"Suzman DL, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int. 2018;38(6):976\u201387. https:\/\/doi.org\/10.1111\/liv.13746.","journal-title":"Liver Int"},{"issue":"10","key":"1170_CR35","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1517\/14740338.2015.1085969","volume":"14","author":"O Abdel-Rahman","year":"2015","unstructured":"Abdel-Rahman O, ElHalawani H, Fouad M. Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Expert Opin Drug Saf. 2015;14(10):1507\u201318. https:\/\/doi.org\/10.1517\/14740338.2015.1085969.","journal-title":"Expert Opin Drug Saf"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01170-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01170-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01170-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T10:20:05Z","timestamp":1656757205000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01170-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1170"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01170-6","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]},"assertion":[{"value":"16 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial support for this research was provided by Bristol Myers Squibb. The study sponsor was involved in several aspects of the research, including the study design, the interpretation of data, the writing of the manuscript, and the decision to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Stephen Huo and Viviana Del Tejo are employees of Bristol Myers Squibb, which funded the development and conduct of this study and manuscript. Ella X. Du, Xiaoran Yang, and Keith A. Betts are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Bristol Myers Squibb. Daniel M. Geynisman received consulting fees from Pfizer, Exelixis, AstraZeneca, Seattle Genetics\/Astellas, Eisai, Merck, Myovant Sciences, and 2nd.MD, as well as research funding from Genentech, Merck, Calithera Biosciences, Astellas Pharma, and Harpoon therapeutics. Mauricio Burotto received consulting fees from Roche\/Genentech, Bristol Myers Squibb, MSD Oncology, Novartis, and AstraZeneca, as well as honoraria from Roche\/Genentech, MSD Oncology, Bristol Myers Squibb, and AstraZeneca. Camillo Porta received consulting fees from Angelini Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, EUSA Pharma, Ipsen, Merck Serono, and MSD, as well as honoraria from Bristol Myers Squibb, EUSA Pharma, General Electric, Ipsen, and MSD, payment for expert testimony from EUSA Pharma and Pfizer, and fees for attending meetings\/travel from Roche. Cristina Suarez received research funding from AB Science, Aragon Pharmaceuticals, Astellas Pharma, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim Espa\u00f1a, Bristol Myers Squibb, Clovis Oncology, Exelixis, Genentech, GlaxoSmithKline, Hoffmann-La Roche, Novartis, Pfizer, and Sanofi-Aventis, as well as honoraria from Astellas Pharma, Bristol Myers Squibb, Hoffmann-La Roche, Ipsen, and Pfizer, and scientific advisory fees from Astellas Pharma, Bayer, Bristol Myers Squibb, EUSA Pharma, Hoffmann-La Roche, Ipsen, MSD, Novartis, Pfizer, and Sanofi-Aventis. Maria T. Bourlon received consulting fees from Bristol Myers Squibb, Asofarma, Eisai, MSD Oncology, Janssen Oncology, Novartis, Bayer, Ferring, as well as honoraria from Asofarma, MSD Oncology, Bristol Myers Squibb, Bayer, Eisai, Janssen Oncology, Ipsen, Pfizer, Merck, Ferring, Tecnofarma, Medicamenta, AstraZeneca, and Astellas Pharma, payment for expert testimony from Asofarma, support for attending meetings\/travel from Asofarma, Janssen-Cilag, MSD Oncology, Bristol Myers Squibb Mexico, Pfizer, Ipsen, and Sanofi, and steering committee honoraria from Bristol Myers Squibb. Toni K. Choueiri participated in Data Safety Monitoring\/Advisory Boards and received grants\/contracts and consulting fees from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVIA, Infinity, Ipsen, Janssen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi\/Aventis, Surface Oncology, Takeda, Tempest, and UpToDate, and declares a leadership or fiduciary role in NCCN, GU Steering Committee, and ASCO\/ESMO, owning stock or stock options in Pionyr, Tempest, Osel, and NuscanDx, institutional patents filed on molecular mutations and immunotherapy response, and ctDNA, medical writing and editorial assistance support which may have been funded in part by Communications companies, mentoring several non-US citizens on research projects with potential funding (in part) from non-US sources\/Foreign Components, and receiving independent funding of drug companies or\/and royalties potentially involved in research around the subject matter. Bradley McGregor received consulting fees from Exelixis, Bristol Myers Squibb, Pfizer, Seattle Genetics, Calithera, EMD Serono, Eisai, Asetellas, Dendreon, Nektar, and Bayer, as well as research funding from Exelixis, Bristol Myers Squibb, Pfizer, Seattle Genetics, and Calithera.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"CheckMate 9ER was approved by the institutional review board or ethics committee at each site and conducted in accordance with Good Clinical Practice guidelines per the International Conference on Harmonisation. All patients provided written informed consent based on Declaration of Helsinki principles.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable. This a post-hoc analysis of previously collected, de-identified data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Code is not available for sharing.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Data are available upon reasonable request. Bristol Myers Squibb\u2019s policy on data sharing may be found at . De-identified and anonymized datasets of clinical trial information, including patient-level data, will be shared with external researchers for proposals that are complete, for which the scientific request is valid and the data are available, consistent with safeguarding patient privacy and informed consent.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"All authors were involved in the conception and design, and\/or analysis and interpretation of the data; the drafting of the paper and revising it critically for intellectual content; and the final approval of the version to be published. All authors agree to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}